Background: Paricalcitol has been proposed for the treatment of secondary hyperparathyroidism in patients with renal failure and vitamin D deficiency (VDD); however, VDD is related to a range of clinical complaints. We aimed to investigate the effects of paricalcitol on body composition in VDD rats. Methods: Thirty adult male rats aged 10 weeks were randomly divided into three groups of 10, comprising control, VDD, and VDD plus paricalcitol (32 ng/rat intraperitoneal injection) (VDD+P), at the Animal Lab of the Endocrinology and Metabolism Research Center, Shiraz, Iran, in 2020. Body composition was assessed after three weeks via serum biochemical tests and dual-energy X-ray absorptiometry. Finally, the data were analyzed by using the paired-sample t test, the one-way ANOVA, and the Tukey post hoc test. Results: Global lean mass and fat mass were lower in the VDD and VDD+P groups than in the controls (p <0.001). Global fat percentage was reduced significantly in the VDD+P group (P=0.029). Conclusion: Paricalcitol reduced global fat mass and fat percentage in a rat model with VDD. Evaluation of insulin and adiponectin levels is suggested to clarify the physiology of paricalcitol in VDD states. |
- Felsenfeld AJ. Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephrol. 1997;8:993-1004. PubMed PMID: 9189868.
- Mucsi I, Hercz G. Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci. 1999;317:405-9. doi: 10.1097/00000441-199906000-00009. PubMed PMID: 10372841.
- Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant. 2013;28:2260-8. doi: 10.1093/ndt/gft227. PubMed PMID: 23787544; PubMed Central PMCID: PMCPMC3769981.
- Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail. 2012;34:297-303. doi: 10.3109/0886022X.2011.647298. PubMed PMID: 22251408.
- Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008;28:97-106. doi: 10.1159/000109398. PubMed PMID: 17914251.
- Jokihaara J, Porsti I, Pajamaki I, Vuohelainen T, Jolma P, Koobi P, et al. Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. J Bone Miner Res. 2006;21:745-51. doi: 10.1359/jbmr.060114. PubMed PMID: 16734389.
- Borrego Utiel FJ, Bravo Soto JA, Merino Perez MJ, Gonzalez Carmelo I, Lopez Jimenez V, Garcia Alvarez T, et al. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Nefrologia. 2015;35:363-73. doi: 10.1016/j.nefro.2015.06.018. PubMed PMID: 26306956.
- Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis. 2000;36:789-96. doi: 10.1053/ajkd.2000.17667. PubMed PMID: 11007682.
- Zilinska Z, Dedinska I, Breza J, Laca L. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers. Iran J Kidney Dis. 2017;11:461-6. PubMed PMID: 29190607.
- Fujii H, Yonekura Y, Nakai K, Kono K, Goto S, Nishi S. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. J Steroid Biochem Mol Biol. 2017;167:55-60. doi: 10.1016/j.jsbmb.2016.11.002. PubMed PMID: 27818277.
- Ali TM, El Esawy B, Elaskary A. Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats. Ir J Med Sci. 2018;187:75-84. doi: 10.1007/s11845-017-1635-7. PubMed PMID: 28551720.
- Molina P, Vizcaino B, Molina MD, Beltran S, Gonzalez-Moya M, Mora A, et al. The effect of high-volume online haemodiafiltration on nutritional status and body composition: the ProtEin Stores prEservaTion (PESET) study. Nephrol Dial Transplant. 2018;33:1223-35. doi: 10.1093/ndt/gfx342. PubMed PMID: 29370428.
- Sarkar SR, Kuhlmann MK, Khilnani R, Zhu F, Heymsfield SB, Kaysen GA, et al. Assessment of body composition in long-term hemodialysis patients: rationale and methodology. J Ren Nutr. 2005;15:152-8. doi: 10.1053/j.jrn.2004.09.038. PubMed PMID: 15648026.
- Festing S, Wilkinson R. The ethics of animal research. Talking Point on the use of animals in scientific research. EMBO Rep. 2007;8:526-30. doi: 10.1038/sj.embor.7400993. PubMed PMID: 17545991; PubMed Central PMCID: PMCPMC2002542.
- Stavenuiter AW, Arcidiacono MV, Ferrantelli E, Keuning ED, Vila Cuenca M, ter Wee PM, et al. A novel rat model of vitamin D deficiency: safe and rapid induction of vitamin D and calcitriol deficiency without hyperparathyroidism. Biomed Res Int. 2015;2015:604275. doi: 10.1155/2015/604275. PubMed PMID: 25815325; PubMed Central PMCID: PMCPMC4359872.
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-6. doi: 10.1038/90984. PubMed PMID: 11479627.
- Bozic M, Guzman C, Benet M, Sanchez-Campos S, Garcia-Monzon C, Gari E, et al. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis. J Hepatol. 2016;65:748-57. doi: 10.1016/j.jhep.2016.05.031. PubMed PMID: 27245430.
|